Literature DB >> 16556247

Prevalence of fibromyalgia syndrome in migraine patients.

G Ifergane1, D Buskila, N Simiseshvely, K Zeev, H Cohen.   

Abstract

Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown aetiology characterized by diffuse pain over more than 3 months and tenderness in specific sites named tender points. The aim of this study was to assess the prevalence and severity of FMS among patients suffering from episodic migraine. Ninety-two consecutive patients (20 male, 72 female) fulfilling the International Headache Society criteria for migraine with and without aura from a tertiary headache clinic were evaluated. A headache and generalized pain history was recorded, tender points were evaluated by thumb palpation. The diagnosis of FMS was made based on the 1990 American College of Rheumatology classification criteria for FMS. Sixteen (22.2%) of the female patients and none of the male patients were diagnosed as suffering from FMS. Migraine severity and characteristics were similar to other female migraine patients. Patients suffering from migraine-FMS had lower quality of life scores and higher levels of mental distress. A high incidence of FMS was found among female migraine patients but not in males. The coexistence of FMS should be considered when choosing a prophylactic migraine therapy.

Entities:  

Mesh:

Year:  2006        PMID: 16556247     DOI: 10.1111/j.1468-2982.2005.01060.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  31 in total

Review 1.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

2.  Application of density estimation algorithms in analyzing co-morbidities of migraine.

Authors:  Meng-Han Yang; Fu-Yi Yang; Yen-Jen Oyang
Journal:  Netw Model Anal Health Inform Bioinform       Date:  2013-02-12

Review 3.  Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis.

Authors:  Fatemeh Heidari; Mahdi Afshari; Mahmood Moosazadeh
Journal:  Rheumatol Int       Date:  2017-04-26       Impact factor: 2.631

Review 4.  Comorbidity in perimenstrual migraine.

Authors:  Marianna Nicodemo; Sabina Cevoli; Giulia Giannini; Pietro Cortelli
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 5.  Neurovascular pains: implications of migraine for the oral and maxillofacial surgeon.

Authors:  Donald R Nixdorf; Ana M Velly; Aurelio A Alonso
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2008-05       Impact factor: 2.802

6.  The prevalence of fibromyalgia and its relation with headache characteristics in episodic migraine.

Authors:  Sami Küçükşen; Emine Genç; Halim Yılmaz; Ali Sallı; İlknur Albayrak Gezer; Ali Yavuz Karahan; Ender Salbaş; Havva Turaç Cingöz; Ömer Nas; Hatice Uğurlu
Journal:  Clin Rheumatol       Date:  2013-02-27       Impact factor: 2.980

7.  Quality of life and emotional functioning in youth with chronic migraine and juvenile fibromyalgia.

Authors:  Susmita Kashikar-Zuck; Marium Zafar; Kimberly A Barnett; Brandon S Aylward; Daniel Strotman; Shalonda K Slater; Janelle R Allen; Susan L Lecates; Marielle A Kabbouche; Tracy V Ting; Andrew D Hershey; Scott W Powers
Journal:  Clin J Pain       Date:  2013-12       Impact factor: 3.442

Review 8.  Fibromyalgia: an update and immunological aspects.

Authors:  Eduardo S Paiva; Evelin Diana Goldenberg Mariano da Costa; Morton Scheinberg
Journal:  Curr Pain Headache Rep       Date:  2008-10

9.  Thickening in the somatosensory cortex of patients with migraine.

Authors:  Alexandre F M DaSilva; Cristina Granziera; Josh Snyder; Nouchine Hadjikhani
Journal:  Neurology       Date:  2007-11-20       Impact factor: 9.910

10.  The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.

Authors:  Carla Ghelardini; Nicoletta Galeotti; Elisa Vivoli; Irene Grazioli; Carla Uslenghi
Journal:  J Headache Pain       Date:  2009-09-15       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.